Tech Center 1600 • Art Units: 1645 1647 1657
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18609420 | METHODS OF TREATING METABOLIC DISORDERS ASSOCIATED WITH LIPODYSTROPHIES AND DEFECTS IN INSULIN PRODUCTION OR SIGNALING | Non-Final OA | Novartis AG |
| 17639862 | TREATMENT OF LIVER DISEASE OR DISORDER COMPRISING ACTRII RECEPTOR ANTAGONISTS | Final Rejection | Novartis AG |
| 19299180 | COMPOSITIONS AND METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION | Non-Final OA | Cavalry Biosciences, Inc. |
| 18026546 | POTENT BINDING AGENTS FOR ACTIVATION OF THE HEDGEHOG SIGNALING PATHWAY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17428995 | TREATMENT OF PATIENTS AT RISK OF RAPID PROGRESSION OF OSTEOARTHRITIS WITH AN FGF-18 COMPOUND | Non-Final OA | MERCK PATENT GMBH |
| 17920118 | PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISEASE | Non-Final OA | Eli Lilly and Company |
| 16625118 | PROMOTING LUNG GROWTH | Final Rejection | Children's Medical Center Corporation |
| 18032479 | NOVEL KLOTHO INTERACTION SITE IN THE C-TERMINUS OF FGF23 | Non-Final OA | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION |
| 17287777 | ANTIBODIES SPECIFIC FOR GLYCOSYLATED APOJ AND USES THEREOF | Final Rejection | Fundació Institut De Recerca De L'Hospital De La Santa Creu l Sant Pau |
| 17794213 | ANTI-ANGPTL3 ANTIBODY AND USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18523811 | Ligand Binding Molecules and Uses Thereof | Non-Final OA | VEGENICS PTY LIMITED |
| 18496279 | Compositions Comprising an Anti-Metallothionein Antibody and a Hepatic Cell Targeting Moiety | Final Rejection | JOSLIN DIABETES CENTER, INC. |
| 18491616 | LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Non-Final OA | YUHAN CORPORATION |
| 17999903 | RHFGF21 FUSION PROTEIN, POLYNUCLEOTIDE ENCODING RHFGF21 FUSION PROTEIN, COMPOSITION CONTAINING RHFGF21 FUSION PROTEIN, AND USE OF RHFGF21 FUSION PROTEIN | Non-Final OA | Jiangsu Kanion Pharmaceutical Co., Ltd. |
| 17788226 | TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES | Non-Final OA | SOTIO BIOTECH A.S. |
| 18256276 | HALF-LIFE EXTENDING COMPOSITIONS AND METHODS | Non-Final OA | Janux Therapeutics, Inc. |
| 18319817 | METHODS AND ANTIBODIES FOR MODULATION OF IMMUNORESPONSE | Non-Final OA | Ascendo Biotechnology, Inc. |
| 18030089 | METHOD OF TREATMENT OF FIBROSIS AND WOUND HEALING | Non-Final OA | RADBIO USA, Inc |
| 17792386 | A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF | Final Rejection | WUXI BIOLOGICS (SHANGHAI) CO. LTD. |
| 18148633 | TREATMENT OF DEMENTIA OR ALZHEIMER'S AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADRENOMEDULLIN ANTIBODY FRAGMENT | Non-Final OA | SPHINGOTEC GMBH |
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | Final Rejection | SphingoTec GmbH |
| 16315805 | ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE | Non-Final OA | Sphingotec GmbH |
| 16646495 | PROADRENOMEDULLIN AS INDICATOR FOR RENAL REPLACEMENT THERAPY IN CRITICALLY ILL PATIENTS | Final Rejection | B.R.A.H.M.S GmbH |
| 17905607 | ANTIGEN-BINDING MOLECULES AND USES THEREOF | Non-Final OA | Scout Bio, Inc. |
| 17905496 | PHARMACEUTICAL FORMULATION COMPRISING BEVACIZUMAB | Non-Final OA | SHANGHAI HENLIUS BIOTECH, INC. |
| 17837920 | Heparin-Associated Polypeptides and Uses Thereof | Non-Final OA | Juvena Therapeutics, Inc. |
| 17606173 | METHODS FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS WITH BEVACIZUMAB LINKED TO HEPARIN | Final Rejection | The University of Massachusetts |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy